Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Graham

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Clinical Genitourinary Cancer|June 23, 2021
Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information SystemIgal Kushnir, Naveen S Basappa, Sunita Ghosh, et al.
The Oncologist|January 24, 2020
Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk GroupMarie-France Savard, J Connor Wells, Jeffrey Graham, et al.
JCO Global Oncology|February 29, 2020
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large CohortsDominick Bossé, Wanling Xie, Xun Lin, et al.
Journal of Geriatric Oncology|February 15, 2026
Real-world management and clinical outcomes of first line treatment of advanced renal cell carcinoma in older patients in CanadaLauren Curry, Sunita Ghosh, Erica Arenovich, et al.
European Urology|August 26, 2019
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database ConsortiumShaan Dudani, Jeffrey Graham, J Connor Wells, et al.
Cancers|February 13, 2025
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status PatientsNoa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, et al.
Clinical Genitourinary Cancer|April 27, 2025
Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World StudyGhady Bou-Nehme Sawaya, Simon Tanguay, Lori A Wood, et al.
European Urology Oncology|December 2, 2019
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint InhibitorsJeffrey Graham, Amishi Y Shah, J Connor Wells, et al.
European Urology Oncology|December 14, 2023
Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic TherapiesGhady Bou-Nehme Sawaya, Alice Dragomir, Lori A Wood, et al.
European Urology|May 5, 2020
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell CarcinomaBimal Bhindi, Jeffrey Graham, J Connor Wells, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Clinical Genitourinary Cancer|June 23, 2021
Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information SystemIgal Kushnir, Naveen S Basappa, Sunita Ghosh, et al.
The Oncologist|January 24, 2020
Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk GroupMarie-France Savard, J Connor Wells, Jeffrey Graham, et al.
JCO Global Oncology|February 29, 2020
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large CohortsDominick Bossé, Wanling Xie, Xun Lin, et al.
Journal of Geriatric Oncology|February 15, 2026
Real-world management and clinical outcomes of first line treatment of advanced renal cell carcinoma in older patients in CanadaLauren Curry, Sunita Ghosh, Erica Arenovich, et al.
European Urology|August 26, 2019
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database ConsortiumShaan Dudani, Jeffrey Graham, J Connor Wells, et al.
Cancers|February 13, 2025
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status PatientsNoa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, et al.
Clinical Genitourinary Cancer|April 27, 2025
Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World StudyGhady Bou-Nehme Sawaya, Simon Tanguay, Lori A Wood, et al.
European Urology Oncology|December 2, 2019
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint InhibitorsJeffrey Graham, Amishi Y Shah, J Connor Wells, et al.
European Urology Oncology|December 14, 2023
Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic TherapiesGhady Bou-Nehme Sawaya, Alice Dragomir, Lori A Wood, et al.
European Urology|May 5, 2020
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell CarcinomaBimal Bhindi, Jeffrey Graham, J Connor Wells, et al.
Pageof 6